{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:06:49Z","timestamp":1778821609658,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2019J01162"],"award-info":[{"award-number":["2019J01162"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020783","name":"Fujian Provincial Federation of Social Sciences","doi-asserted-by":"publisher","award":["2100201"],"award-info":[{"award-number":["2100201"]}],"id":[{"id":"10.13039\/501100020783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.brachy.2023.06.229","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T23:34:16Z","timestamp":1691796856000},"page":"858-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Long-Wang","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le-Ye","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Zhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6397-7877","authenticated-orcid":false,"given":"Jun-Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.brachy.2023.06.229_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.brachy.2023.06.229_bib0002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijsu.2015.05.009","article-title":"The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus","volume":"20","author":"Zhang","year":"2015","journal-title":"Int J Surg"},{"issue":"9","key":"10.1016\/j.brachy.2023.06.229_bib0003","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.brachy.2023.06.229_bib0004","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/j.1572-0241.2005.00229.x","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma","volume":"100","author":"Yeung","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.brachy.2023.06.229_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.635731","article-title":"The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.229_bib0006","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"European Organisation For R, treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.229_bib0007","first-page":"299","article-title":"Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy","volume":"72","author":"Eskens","year":"2014","journal-title":"Neth J Med"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000503685","article-title":"Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 edition)","volume":"9","author":"Cheng","year":"2020","journal-title":"Liver Cancer"},{"issue":"10126","key":"10.1016\/j.brachy.2023.06.229_bib0009","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.brachy.2023.06.229_bib0010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.hbpd.2021.12.004","article-title":"Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review","volume":"21","author":"Tao","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"10","key":"10.1016\/j.brachy.2023.06.229_bib0011","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4161\/cbt.12.10.17676","article-title":"Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed","volume":"12","author":"Chuan-Xing","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0012","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3748\/wjg.v22.i1.407","article-title":"Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review","volume":"22","author":"Han","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1148\/radiol.14131946","article-title":"Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib\u2013a retrospective controlled study","volume":"272","author":"Zhu","year":"2014","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.brachy.2023.06.229_bib0014","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.brachy.2023.06.229_bib0015","article-title":"Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients","author":"Liu","year":"2014","journal-title":"Biomed Res Int"},{"issue":"12","key":"10.1016\/j.brachy.2023.06.229_bib0016","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/j.crad.2014.09.007","article-title":"Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus","volume":"69","author":"Pan","year":"2014","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12957-021-02401-4","article-title":"Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review","volume":"19","author":"Shao","year":"2021","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.brachy.2023.06.229_bib0018","article-title":"Combination of sorafenib, camrelizumab, transcatheter arterial chemoembolization, and stereotactic body radiation therapy as a Novel Downstaging strategy in advanced hepatocellular carcinoma with portal vein tumor thrombus: a case series study","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2023.06.229_bib0019","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunoly"},{"key":"10.1016\/j.brachy.2023.06.229_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221075174","article-title":"A retrospective study on therapeutic efficacy of transarterial chemoembolization combined with immune checkpoint inhibitors plus lenvatinib in patients with unresectable hepatocellular carcinoma","volume":"21","author":"Teng","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.brachy.2023.06.229_bib0021","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.brachy.2023.06.229_bib0022","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.2147\/OTT.S139571","article-title":"CT-guided (125)I interstitial brachytherapy for pelvic recurrent cervical carcinoma after radiotherapy","volume":"10","author":"Tong","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12072-015-9663-8","article-title":"Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus","volume":"10","author":"Luo","year":"2016","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.brachy.2023.06.229_bib0024","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00432-010-0821-z","article-title":"Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma","volume":"136","author":"Li","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.brachy.2023.06.229_bib0025","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1007\/s00330-015-4198-x","article-title":"Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study","volume":"26","author":"Huang","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.brachy.2023.06.229_bib0026","article-title":"Locoregional combined with systemic therapies for advanced hepatocellular carcinoma: an inevitable trend of rapid development","volume":"8","author":"Li","year":"2021","journal-title":"Front Mol Bioscis"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","article-title":"A new classification for hepatocellular carcinoma with portal vein tumor thrombus","volume":"18","author":"Shi","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"21","key":"10.1016\/j.brachy.2023.06.229_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.229_bib0029","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/cancers12040791","article-title":"Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update","volume":"12","author":"Kishore","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0031","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.brachy.2023.06.229_bib0032","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.brachy.2023.06.229_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2141859","article-title":"Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study","volume":"2019","author":"Yuan","year":"2019","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.229_bib0034","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/hepr.12123","article-title":"Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma","volume":"44","author":"Miyahara","year":"2014","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.229_bib0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14737140.2023.2181162","article-title":"TKIs in combination with immunotherapy for hepatocellular carcinoma","volume":"23","author":"Stefanini","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1016\/j.brachy.2023.06.229_bib0036","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1016\/S1470-2045(20)30476-9","article-title":"Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - authors' replys","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.brachy.2023.06.229_bib0037","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.brachy.2023.06.229_bib0038","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.229_bib0039","doi-asserted-by":"crossref","first-page":"e1214","DOI":"10.1002\/ctm2.1214","article-title":"Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis","volume":"13","author":"Wang","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.brachy.2023.06.229_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.874473","article-title":"Efficacy and safety of TACE combined with lenvatinib plus PD-1 inhibitors compared with TACE alone for unresectable hepatocellular carcinoma patients: a prospective cohort study","volume":"12","author":"Qu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2023.06.229_bib0041","article-title":"Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in China real-world","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.brachy.2023.06.229_bib0042","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.brachy.2023.06.229_bib0043","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.229_bib0044","first-page":"618","article-title":"[Safety and efficacy of TIPS combined with iodine-125 seed strands in the treatment of patients with hepatocellular carcinoma combined with portal vein tumor thrombosis]","volume":"30","author":"Weng","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"31","key":"10.1016\/j.brachy.2023.06.229_bib0045","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.3748\/wjg.v25.i31.4360","article-title":"Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: beyond the known frontiers","volume":"25","author":"Cerrito","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.brachy.2023.06.229_bib0046","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1097\/MD.0000000000003015","article-title":"Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.brachy.2023.06.229_bib0047","article-title":"Radiation therapy in the era of immune treatment for hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.brachy.2023.06.229_bib0048","article-title":"Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.brachy.2023.06.229_bib0049","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/cancers15010050","article-title":"Stereotactic body radiation therapy (SBRT) plus immune checkpoint inhibitors (ICI) in hepatocellular carcinoma and cholangiocarcinoma","volume":"15","author":"Jiang","year":"2022","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.brachy.2023.06.229_bib0050","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.3390\/cancers14153619","article-title":"A combination of sorafenib, an immune checkpoint inhibitor, TACE and stereotactic body radiation therapy versus sorafenib and TACE in advanced hepatocellular carcinoma accompanied by portal vein tumor thrombus","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.229_bib0051","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s12072-022-10423-7","article-title":"Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial","volume":"16","author":"Guo","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.brachy.2023.06.229_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.brachy.2023.06.229_bib0053","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00270-021-02887-1","article-title":"Integrated I-125 seed implantation combined with transarterial chemoembolization for treatment of hepatocellular carcinoma with main portal vein tumor thrombus","volume":"44","author":"Wang","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.brachy.2023.06.229_bib0054","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3892\/ol.2020.11765","article-title":"Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I-125 seed implantation on liver cancer","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol Letters"},{"issue":"10","key":"10.1016\/j.brachy.2023.06.229_bib0055","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s00270-019-02256-z","article-title":"Safety and feasibility of helical I-125 seed implants combined with transcatheter arterial chemoembolization in hepatocellular carcinomas with main portal vein tumor thrombus","volume":"42","author":"Wang","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.229_bib0056","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/hep.31840","article-title":"Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors","volume":"74","author":"Cheu","year":"2021","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.brachy.2023.06.229_bib0057","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/cncr.32339","article-title":"Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","volume":"125","author":"Feun","year":"2019","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.brachy.2023.06.229_bib0058","doi-asserted-by":"crossref","first-page":"11315","DOI":"10.1002\/cam4.5841","article-title":"Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features","volume":"12","author":"Zou","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.brachy.2023.06.229_bib0059","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s12325-023-02449-6","article-title":"Evaluating the benefits of TACE combined with lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus","volume":"40","author":"Zou","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.brachy.2023.06.229_bib0060","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/OTT.S192572","article-title":"Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials","volume":"12","author":"Casadei Gardini","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10.1016\/j.brachy.2023.06.229_bib0061","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.2016.69.5197","article-title":"Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials","volume":"35","author":"Jackson","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123015970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123015970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:08:40Z","timestamp":1778818120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472123015970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1538472123015970"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2023.06.229","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2023.06.229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}